Biotech Values

[mcbio]

I don’t know but I’ll try to find out. Did you end up buying any shares?

Thanks DD. No, I haven't yet bought any shares but I am still keeping an eye on Medivir and have them up near the top of my watchlist. I still think Medivir is the best play right now in the HCV space, given their position and valuation. I think the biggest risks to Medivir's valuation are the usual risks of a safety issue cropping up in Phase 3 trials, or in the combo trial with the VRUS nuke, or growing belief that the VRUS nukes alone will dominate future HCV treatment.